Suzuki Shinya, Otsuka Takayuki, Sagara Koichi, Semba Hiroaki, Kano Hiroto, Matsuno Shunsuke, Takai Hideaki, Kato Yuko, Uejima Tokuhisa, Oikawa Yuji, Nagashima Kazuyuki, Kirigaya Hajime, Kunihara Takashi, Yajima Junji, Sawada Hitoshi, Aizawa Tadanori, Yamashita Takeshi
Department of Cardiovascular Medicine, The Cardiovascular Institute.
Circ J. 2015;79(10):2274-7. doi: 10.1253/circj.CJ-15-0386. Epub 2015 Aug 27.
The association between ABO blood type and the activated partial thromboplastin time (aPTT) under dabigatran therapy in nonvalvular atrial fibrillation (NVAF) patients is unclear.
Between 2011 March and 2015 May, data on ABO blood type and aPTT under dabigatran were obtained for 396 NVAF patients (baseline aPTT, 166). The prevalence of blood type O tended to increase or significantly increase according to baseline aPTT, aPTT under dabigatran, and their difference (∆aPTT) (P=0.054, 0.001, and 0.012, respectively).
In these NVAF patients, a high aPTT value under dabigatran therapy was associated with blood type O.
在非瓣膜性心房颤动（NVAF）患者中，ABO血型与达比加群治疗下活化部分凝血活酶时间（aPTT）之间的关联尚不清楚。
在2011年3月至2015年5月期间，获取了396例NVAF患者（基线aPTT，166）的ABO血型和达比加群治疗下aPTT的数据。根据基线aPTT、达比加群治疗下的aPTT及其差值（∆aPTT），O型血的患病率呈上升趋势或显著上升（P分别为0.054、0.001和0.012）。
在这些NVAF患者中，达比加群治疗下较高的aPTT值与O型血相关。
